Advertisement

Topics

Entasis Therapeutics Holdings Inc. Company Profile

10:47 EST 19th November 2018 | BioPortfolio

Entasis Therapeutics is developing a portfolio of innovative cures for serious drug-resistant bacterial infections, a global health crisis affecting the lives of millions of patients. Entasis’ anti-infective discovery platform has produced a pipeline of meaningfully differentiated programs which target serious bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), a Non-Beta-lactam PBP inhibitor (targeting Gram-negative infections), and zoliflodacin (targeting Neisseria gonorrhoeae). www.entasistx.com


News Articles [1228 Associated News Articles listed on BioPortfolio]

Entasis files for IPO

Antibiotics developer Entasis Therapeutics Holdings Inc. filed for its initial public offering.

Entasis nets $70mm via IPO

Antibiotics developer Entasis Therapeutics Holdings Inc. netted $69.75mm in its initial public offering of 5mm common shares priced at $15. The company had planned to sell 4.4mm shares between $16 and...

Entasis Therapeutics and Principia Biopharma Join the IPO Queue

IPO activity has waned in the dog days of summer, but two more biotechs have now joined the growing list of companies with Wall Street ambitions. Entasis Therapeutics and Principia Biopharma have file...

IPO pulls in $75M for antibiotics firm Entasis

An initial public offering pulled in $75 million for AstraZeneca spinoff Entasis Therapeutics.  -More- 

Entasis seeks to raise $86.3M in IPO

An initial public offering was filed by Entasis Therapeutics seeking to raise $86.3 million.  -More- 

Entasis begins Phase I trial of ETX0282 and ETX0282CPDP to treat infections

Entasis Therapeutics has commenced a Phase I clinical trial evaluating ETX0282 in combination with ETX0282CPDP to treat infections caused by...Read More... The post Entasis begins Phase I trial of ETX...

Entasis to Present on ETX2514SUL at #IDWeek2018 $ETTX https://globenewswire.com/news-release/2018/10/03/1600674/0/en/Entasis-Therapeutics-to-Present-on-ETX2514SUL-at-IDWeek-2018.html …

Entasis to Present on ETX2514SUL at #IDWeek2018 $ETTX https://globenewswire.com/news-release/2018/10/03/1600674/0/en/Entasis-Therapeutics-to-Present-on-ETX2514SUL-at-IDWeek-2018.html …

Entasis Therapeutics Initiates U.S. IPO Efforts

PubMed Articles [473 Associated PubMed Articles listed on BioPortfolio]

Antibiotic use on German pig farms - A longitudinal analysis for 2011, 2013 and 2014.

To study antibiotic use in livestock in a temporal context with the development of antimicrobial resistance, long-term changes in antibiotic use must be mapped and their possible causes must be explor...

Destroyed by Slavery? Slavery and African American Family Formation Following Emancipation.

This study introduces a new sample that links people and families across 1860, 1880, and 1900 census data to explore the intergenerational impact of slavery on black families in the United States. Sla...

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

Six-Year Prospective Outcomes of Primary Breast Augmentation With Nano Surface Implants.

Motiva Implants (Establishment Labs Holdings Inc.) are a novel family of silicone breast implants using cutting-edge technologies engineered to optimize aesthetic and safety outcomes.

RNA-targeted therapeutics for lipid disorders.

To summarize recent developments in the field of RNA-directed therapeutics targeting lipid disorders that are not effectively managed.

Clinical Trials [166 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1723 Associated Companies listed on BioPortfolio]

Entasis Therapeutics Holdings Inc.

Entasis Therapeutics is developing a portfolio of innovative cures for serious drug-resistant bacterial infections, a global health crisis affecting the lives of millions of patie...

Entasis Therapeutics Inc.

Entasis Therapeutics is developing a portfolio of innovative cures for serious drug-resistant bacterial infections, a global health crisis affecting the lives of millions of patie...

Auven Therapeutics

Auven Therapeutics is a private equity company focused on the healthcare industry. The Company’s strategy is to acquire controlling ownership in promising therapeutic products or platforms. ...

Pernix Therapeutics Holdings, Inc.

Pernix Therapeutics Holdings, Inc. is a specialty pharmaceutical company primarily focused on serving the needs of the pediatric marketplace. Commercially-proven branded product f...

InVivo Therapeutics Holdings Corp.

InVivo Therapeutics Holdings Corp. is a Cambridge, MA medical device company focused on utilizing polymers as a platform technology to develop treatments to improve function in in...

More Information about "Entasis Therapeutics Holdings Inc." on BioPortfolio

We have published hundreds of Entasis Therapeutics Holdings Inc. news stories on BioPortfolio along with dozens of Entasis Therapeutics Holdings Inc. Clinical Trials and PubMed Articles about Entasis Therapeutics Holdings Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Entasis Therapeutics Holdings Inc. Companies in our database. You can also find out about relevant Entasis Therapeutics Holdings Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record